to on-pump coronary artery bypass (ONCAB) in the mid/long term as opposed to short-term outcomes.[ 7 ] In the coronary trial which was a randomized controlled trial of ONCAB versus OPCAB with a study population across 16 countries, OPCAB was clearly beneficial in preventing AKIN Stage I AKI-CS with a strong trend toward preventing AKIN Stages 2/3 at 30 days.[ 8 ] However, there was no protection from renal failure requiring dialysis either in the short or intermediate term.[ 8 ] Further, in all prevalence studies of AKI-CS, there is divergence on account of patient enrolment and definitions of the condition, the nature and types of surgery which the individuals underwent.
← all excerpts
Predictors of acute kidney injury in patients undergoing adult cardiac surgery.
1
—
—